SF 364 (see companion bill HF 284) – Minnesota

Status: Inactive / Dead
Year Introduced: 2019
Link: https://www.revisor.mn.gov/bills/bill.php?b=Senate&f=SF0364&ssn=0&y=2019

Insulin products commissioner of health costs review authorization; excess costs determination; maximum reimbursement level establishment; appropriation. This bill establishes a process for the commissioner of health to review the cost of insulin products made available for sale in the state, determine if the cost of a product has led or
will lead to excess costs for health care systems in the state, and establish a maximum level of reimbursement for an insulin product that the commissioner finds has led or will
lead to excess costs for health care systems. Excess cost is defined as a cost that is not sustainable to public and private health care systems over a ten-year period.

Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found